TriLink Biotechnologies said today that it has recently been awarded a Phase I SBIR grant worth approximately $100,000 by the National Institutes of Health to develop a hot-start approach for the ligase chain reaction method.

Under the six-month grant, administered by the National Institute of General Medical Sciences, TriLink will incorporate chemically modified ligation components, including oligonucleotide probes and cofactors, containing thermally labile protecting groups for heat-triggered LCR.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.